The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known (although it is much debated). In a new paper in the Annals of Oncology, Thomsen et al. have used data from patients in the […]![]()
